Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Phase 2bexobrutinibNeutral

AI Analysis

Summary

Nurix Therapeutics is enrolling patients in the Phase 2 DAYBreak CLL-201 trial of bexobrutinib in relapsed/refractory chronic lymphocytic leukemia with the goal of supporting Accelerated Approval.

Clinical Trial Data

Phase

Phase 2

Outcome Details

Phase 2 DAYBreak CLL-201 trial enrolling, designed to support Accelerated Approval

Importance:5/10

Sentiment:

0.00

Phase 2Accelerated Approval pathwayChronic lymphocytic leukemiaClinical trial enrollmentCorporate update

Related Companies

$NRIX

Read the original article

Published by GlobeNewswire Pharma on April 8, 2026 10:00 AM

Read Original